Consulting Services
For Investors
- Lucid Diligence Briefs
- Venture Capital
Case Studies
Insights
- Conference Previews
- Conference Social Media Reports
BioPharma and Tech News
LucidSearch
QuickAnswers

Contact Us

Search

T1D

EASD 2025 Preview: Key Diabetes Highlihts to Watch

EASD 2025 at a glance In the lead-up to EASD 2025, LucidQuest spotlights…

Endocrinology

Endocrinology Weekly Update - July 15th 2025

🧬 Endocrinology Update: Stem Cell T1D Breakthrough, Smart Glucose Wearable,…

Endocrinology

Endocrinology Weekly Update - July 1st 2025

🧬 Endocrinology Update: Mifepristone Lowers A1c, Gene Therapy for Diabetes,…

Endocrinology

Endocrinology Weekly Update - May 20th 2025

🧬 Endocrinology Update: Mounjaro, Cell Therapy, Diabetes Tech & More From…

Endocrinology

Endocrinology Weekly News - April 15th 2025

Need-to-Know Endocrinology Updates In this episode, we cover the most important…

Categories

Obesity News
Endocrinology News
Our Insights
Immunology News
Case studies
Hematology News
BioPharma and Tech News
Oncology News
BioPharma Strategy, CI and AI Guides
Lucid Diligence Brief
Conference Social Media Reports
Venture Capital
AI in Healthcare and Digital Health
Conference Previews
Cell and Gene Therapy News
Rare Disease News
Neuroscience News
Women's Health News
Public Health News
Respiratory News
Cardiovascular News
Vaccine news

Recent Posts

Obesity Review 2025: The Rise of Oralization, the Muscle Question, and a New Era of Access Pressure
Lucid Diligence Brief: Truemed $34m Series A to scale payment integration platform
Lucid Diligence Brief: Jacobio and AstraZeneca pan-KRAS asset deal
Oncology 2025 Review: Curative-Intent Expansion, ADC Acceleration, and the Operationalization of Immunotherapy
Lucid Diligence Brief: BioMarin to acquire Amicus Therapeutics for $4.8B

Tags

ADC therapy Allurion Angelman Syndrome Annamycin ASGCT 2025 BCI CAP-002 Causal AI Cedars-Sinai CellCentric Chemical Pollution Competitor Research contraceptives CPAP DHEA-S digital pathology EEG European Society of Cardiology exclusivity HAE insulin access ISC 2025 Kite Gilead Mandos Health mCRC Meningeal Neutrophils Mortality Crisis MS Pharma Nippon Shinyaku nmCRPC OCD osteoporosis detection OX40 Oxytocin PD-1/VEGF bispecific phage therapy Pharmaceutical Brands Prefusion F Preterm birth quetiapine XR Saxenda Setmelanotide Strive Health surgical tech VSee

Archives

Archives

LucidQuest Ventures

Accelerate Your Success

LATEST NEWS

Obesity Review 2025: The Rise of Oralization, the Muscle Question, and a New Era of Access Pressure
Lucid Diligence Brief: Truemed $34m Series A to scale payment integration platform
Lucid Diligence Brief: Jacobio and AstraZeneca pan-KRAS asset deal
Oncology 2025 Review: Curative-Intent Expansion, ADC Acceleration, and the Operationalization of Immunotherapy
Lucid Diligence Brief: BioMarin to acquire Amicus Therapeutics for $4.8B

TAGS

ADC therapy Allurion Angelman Syndrome Annamycin ASGCT 2025 BCI CAP-002 Causal AI Cedars-Sinai CellCentric Chemical Pollution Competitor Research contraceptives CPAP DHEA-S digital pathology EEG European Society of Cardiology exclusivity HAE insulin access ISC 2025 Kite Gilead Mandos Health mCRC Meningeal Neutrophils Mortality Crisis MS Pharma Nippon Shinyaku nmCRPC OCD osteoporosis detection OX40 Oxytocin PD-1/VEGF bispecific phage therapy Pharmaceutical Brands Prefusion F Preterm birth quetiapine XR Saxenda Setmelanotide Strive Health surgical tech VSee

Consulting Services
For Investors
- Lucid Diligence Briefs
- Venture Capital
Case Studies
Insights
- Conference Previews
- Conference Social Media Reports
BioPharma and Tech News
LucidSearch
QuickAnswers

© 2025 LucidQuest Ventures. All rights reserved

We use cookies from third party services to offer you a better experience. Read about how we use cookies and how you can control them by clicking "Privacy Preferences".

Privacy Preference Center

Privacy Preferences

When you visit any website, it may store or retrieve information on your browser in the form of cookies. Since we respect your right to privacy, you can choose not to permit data collection from certain types of services. However, not allowing these services may impact your experience ans we are able to offer you.

Privacy Policy

Required

You read and agreed to our Privacy Policy

Tracking

We use third-party cookies that help us analyze and understand how you use this website. These cookies do not store any personal information.

Privacy Policy